Oropharyngeal squamous cell carcinoma (OPSCC) is a kind of squamous cell carcinoma of head and neck, and its incidence is on the rise in recent years. A variety of prognostic markers for OPSCC have been reported in many studies, but they are expensive or difficult to obtain. So, we retrospectively studied the prognostic significance of cytokeratin 19 soluble fragment (Cyfra21-1) in patients with OPSCC, in order to provide theoretical basis for accurate prognosis assessment. A retrospective analysis of the clinicopathological data of 85 OPSCC patients with concurrent radiotherapy and chemotherapy (CRT) admitted from January 2010 to June 2017. Serum Cyfra21-1 levels were measured before treatment. Analyze the relationship between Cyfra21-1 and clinical pathological characteristics of patients. The receiver operating characteristic (ROC) curve was used to calculate the cut-off value of Cyfra21-1. The Cox proportional hazard model was used to conduct univariate and multivariate analysis of related prognostic factors, and to determine the factors related to overall survival (OS) and progression-free survival (PFS). The cutoff value for Cyfra21-1 was 2.93 ng/mL. The baseline data of patients in different Cyfra21-1 groups were balanced and comparable. In the univariate and multivariate analyses, it was found that Cyfra21-1 was associated with OS and PFS. A measurement of Cyfra21-1 ≥2.93 ng/mL indicated poor OS (P<0.001) and PFS (P=0.001). After adjusting for age and disease stage, Cyfra21-1 can independently affect the OS (HR =3.57, 95% CI 1.60-7.99, P=0.002) and PFS (HR =2.89, 95% CI 1.41-5.91, P=0.004) of patients with OPSCC treated with CRT. Pre-treatment Cyfra21-1 can be used as a prognostic marker for patients with OPSCC treated with CRT, which has important clinical significance.Pre-treatment Cyfra21-1 can be used as a prognostic marker for patients with OPSCC treated with CRT, which has important clinical significance. Survival after resection of hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) still remains poor. Apatinib, a vascular endothelial cell growth factor receptor 2 inhibitor, has been shown to be safe and effective in patients with advanced HCC, so in the present study its efficacy and safety in the adjuvant setting was explored. In this single-center, open-label phase II trial, the patients received apatinib (500 mg/day) until they experienced disease recurrence or intolerable toxicity. The primary endpoint was recurrence-free survival (RFS); the secondary endpoints included overall survival (OS) and safety. From a total of 49 patients who were screened between August 2017 and December 2018, 30 study participants received apatinib. According to the Liver Cancer Study Group of Japan classification of PVTT, there were 7, 11, and 12 participants with Vp1, Vp2, and Vp3, respectively. The median duration of treatment was 4.8 months [interquartile range (IQR) 2.0-8.8], and the median dose of apatinib was 339.7 mg/day (IQR 267.7-500 mg/day). The median follow-up was 14.3 months (IQR 12.3-19.3). check details The median RFS was 7.6 months [95% confidence interval (CI) 5.7-9.5 months]. The 1-year RFS rate and the 1-year OS rate were 36.1% and 93.3%, respectively. A total of 29 (96.7%) patients experienced adverse events, and 14 (46.7%) had grade 3 or 4 adverse events. No treatment-related deaths occurred. Apatinib was well tolerated in patients after resection of HCC with PVTT. The median RFS in this group was improved compared with that previously reported. No. NCT03261791 (ClinicalTrials.gov).No. NCT03261791 (ClinicalTrials.gov). Autologous nerve transplantation has become the gold standard for other nerve repair methods. But conventional epineurial sutures is prone to misaligned sutures, erroneous axonal growth, and unsatisfactory repair. Finding a new, more effective nerve coaptation method to improve the efficacy of peripheral nerve repair remains an urgent clinical challenge. In this study, the repair efficacies of oblique nerve coaptations for sciatic nerve injury at various angles were observed, providing a theoretical foundation for further clinical applications. Sixty-four Sprague-Dawley rats were randomized into four groups of 16. The autologous nerve transplantation model was established by severing and rejoining in situ a 10-mm segment of the sciatic nerve trunk at the angle of 30° (group A), 45° (group B), 60° (group C), or 90° (group D). Sciatic function index (SFI) measurement, measurement of the recovery rate of the wet weight of the triceps surae, electrophysiological examination of nerves, histological examinations, and image analysis were carried out 12 weeks after surgery. The SFI, the recovery rate of the wet weight of the triceps surae, the electrophysiological function of nerves, histological examinations, and image analysis 12 weeks after surgery indicated that all indices of groups A and B were significantly better than those of groups C and D (P<0.05). There was no significant difference between groups A and B or between groups C and D (P>0.05), although group C exhibited a trend of better recovery than group D. Oblique nerve coaptation at 30-45° in autologous nerve transplantation may significantly enhance nerve regeneration.Oblique nerve coaptation at 30-45° in autologous nerve transplantation may significantly enhance nerve regeneration. A few models have been proposed for the prediction of the risk of post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP), but many include factors that are not assessed routinely. Herein, we intend to develop and validate a predictive model for the occurrence of PEP. Data of patients who underwent endoscopic retrograde cholangiopancreatography (ERCP) from January 01, 2016 to May 16, 2019 (training set and internal test set) and from May 17, 2019 to December 25, 2019 (external test set) were retrospectively collected. The performance of the model was validated in the two validation cohorts. A total of 342 patients were included for the external test set, and 47 (13.7%) developed PEP. The variables included in the scoring system were gastrectomy history, high direct bilirubin (DBIL), high albumin (ALB), villous type of papillary orifice, nodular type of papillary orifice, pancreatic guidewire passages, precut sphincterotomy, and high operator experience. A total score >5 indicated high risk.